Hopkins, A.M.; Kichenadasse, G.; Abuhelwa, A.Y.; McKinnon, R.A.; Rowland, A.; Sorich, M.J.
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176.
https://doi.org/10.3390/cancers13051176
AMA Style
Hopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ.
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers. 2021; 13(5):1176.
https://doi.org/10.3390/cancers13051176
Chicago/Turabian Style
Hopkins, Ashley M., Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, and Michael J. Sorich.
2021. "Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial" Cancers 13, no. 5: 1176.
https://doi.org/10.3390/cancers13051176
APA Style
Hopkins, A. M., Kichenadasse, G., Abuhelwa, A. Y., McKinnon, R. A., Rowland, A., & Sorich, M. J.
(2021). Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers, 13(5), 1176.
https://doi.org/10.3390/cancers13051176